1. Field of the Invention
Disclosed herein are methods and apparatuses for sterilization of medical devices using radiation.
2. Description of the State of the Art
Disclosed herein are radially expandable endoprostheses adapted to be implanted in a bodily lumen. An “endoprosthesis” corresponds to an artificial device that is placed inside the body. A “lumen” refers to a cavity of a tubular organ such as a blood vessel.
A stent is an example of such an endoprosthesis. Stents are generally cylindrically shaped devices, which function to hold open and sometimes expand a segment of a blood vessel or other anatomical lumen such as urinary tracts and bile ducts. Stents are often used in the treatment of atherosclerotic stenosis in blood vessels. “Stenosis” refers to a narrowing or constriction of the diameter of a bodily passage or orifice. In such treatments, stents reinforce body vessels and prevent restenosis following angioplasty in the vascular system. “Restenosis” refers to the reoccurrence of stenosis in a blood vessel or heart valve after it has been treated (as by balloon angioplasty, stenting, or valvuloplasty) with apparent success.
The treatment of a diseased site or lesion with a stent involves both delivery and deployment of the stent. “Delivery” refers to introducing and transporting the stent through a bodily lumen to a region, such as a lesion, in a vessel that requires treatment. “Deployment” corresponds to the expanding of the stent within the lumen at the treatment region. Delivery and deployment of a stent are accomplished by positioning the stent about one end of a catheter, inserting the end of the catheter through the skin into a bodily lumen, advancing the catheter in the bodily lumen to a desired treatment location, expanding the stent at the treatment location, and removing the catheter from the lumen.
The structure of a stent is typically composed of scaffolding that includes a pattern or network of interconnecting structural elements often referred to in the art as struts or bar arms. The scaffolding can be formed from wires, tubes, or sheets of material rolled into a cylindrical shape. The scaffolding is designed so that the stent can be radially compressed (to allow crimping) and radially expanded (to allow deployment). A conventional stent is allowed to expand and contract through movement of individual structural elements of a pattern with respect to each other.
Additionally, a medicated stent may be fabricated by coating the surface of either a metallic or polymeric scaffolding with a polymeric carrier that includes an active or bioactive agent or drug. The polymeric scaffolding may also serve as a carrier of an active agent or drug.
After a stent is fabricated, a stent or a stent-catheter device typically undergoes sterilization to reduce the bioburden of the stent to an acceptable sterility assurance level (SAL). There are numerous methods of sterilizing medical devices such as stents, the most common being ethylene oxide treatment and treatment with ionization radiation such as electron beam (E-beam) and gamma radiation.
There is a desire to make E-beam sterilization commercially feasible for polymeric stents. As medical devices increase in complexity, sterilization process technology becomes imperative. A commercially feasible E-beam sterilization process that is compatible with existing E-beam facilities is desired. Also desired is a fixture apparatus having the capability of processing a large volume of medical devices in a short period of time, robustness to human error, and reproducibility of dose from device to device.
Various embodiments of the present invention include a method of radiation sterilizing a plurality of stent-catheter assemblies, the method comprising: positioning a plurality of stent-catheter assemblies on a fixture, each of the stent catheter assemblies being arranged in a planar configuration and disposed in corresponding planar packages supported on the fixture, wherein the packages are stacked horizontally on the fixture; and exposing the packages to an incoming radiation beam, the radiation beam being at an acute angle to the planes of the planar configuration of the assemblies, wherein the packages are arranged such that a front end of the stack faces the radiation beam and a back end of the stack faces away from the radiation beam.
Further embodiments of the present invention include a method of radiation sterilizing a plurality of medical devices, the method comprising: positioning a plurality medical devices on a fixture; and exposing the devices to an incoming radiation beam through movement of the plurality of devices with respect to a radiation source, wherein the number of devices through which the radiation beam passes varies with the movement, wherein a radiation shield is positioned such that a variation in radiation exposure among the medical devices from incoming or backscattered radiation is reduced.
a) is a schematic illustration of a front view of a fixture for supporting two packages, each package containing a stent-catheter assembly.
b) depicts an overhead view of a fixture of
c) depicts a photograph an overhead view of a fixture supporting two chipboard boxes.
a) depicts a schematic illustration of a front view of multiple packages supported by a fixture, each package containing a stent-catheter assembly.
b) depicts an overhead view of the fixture of
c) depicts an overhead view of the fixture of
d) is a schematic illustration of a front view of the fixture of
Radiation sterilization is well known to those of ordinary skill in the art. Medical devices composed in whole or in part of polymers can be sterilized by various kinds of radiation, including, but not limited to, electron beam (E-beam), gamma ray, ultraviolet, infra-red, ion beam, x-ray, and laser sterilization. Generally, it is desirable to increase the throughput of sterilization processes to increase the manufacturing efficiency.
Various embodiments of the present invention relate to the sterilization of multiple medical devices. Such medical devices include implantable medical devices and delivery systems for such devices. The methods described herein may be applied generally to polymeric implantable medical devices, such as for stents, in particular polymeric stents. The methods reduce or narrow the range of radiation exposure from device to device.
Therefore, each device may be irradiated within a specified or selected range. This is of particular importance for polymeric devices, since exposure to radiation above a specified range can cause undesirable degradation of chemical and mechanical properties of a polymer. The methods discussed herein reduce the likelihood of irradiation outside a specified range, causing an undesirable increase in temperature and a corresponding undesirable degree of degradation.
The methods disclosed herein may be applied in combination with a reduced temperature sterilization process in which a device is cooled before, during, and/or after sterilization. The reduced temperature can be below ambient temperature during sterilization. The methods disclosed herein may be applied to a sterilization process using various kinds of radiation.
Examples of implantable medical devices include, but are not limited to, self-expandable stents, balloon-expandable stents, stent-grafts, grafts (e.g., aortic grafts), artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation, Santa Clara, Calif.). The underlying structure or substrate of the device can be of virtually any design.
A stent such as stent 100 may be fabricated from a polymeric tube or a sheet by rolling and bonding the sheet to form a tube. A stent pattern may be formed on a polymeric tube by laser cutting a pattern on the tube. Representative examples of lasers that may be used include, but are not limited to, excimer, carbon dioxide, and YAG. In other embodiments, chemical etching may be used to form a pattern on a tube.
Sterilization is typically performed on implantable medical devices, such as stents and catheters, to reduce the bioburden on the device. Bioburden refers generally to the number of microorganisms that contaminate an object. The degree of sterilization is typically measured by a Sterility Assurance Level (“SAL”), referring to the probability of a viable microorganism being present on a device unit after sterilization. A sterilization dose can be determined by selecting a dose that provides a required “SAL”. The required SAL for a device is dependent on the intended use of the device. For example, a device to be used in the body's fluid path is considered a Class III device. SALs for various medical devices can be found in materials from the Association for the Advancement of Medical Instrumentation (AAMI) in Arlington, Va. In one embodiment, the sterility assurance level for biodegradable stents is at a radiation dose from about 20 kGy to about 30 kGy.
A stent is typically sterilized after being mounted onto a delivery system or device, such as a catheter. Stents are also typically sterilized, packaged, stored, and transported in a “ready to implant” configuration in which the stent is disposed at the distal end of a catheter. However, the methods described are not limited to sterilizing a mounted stent.
The embodiments described herein may be used for sterilizing various kinds of devices, such as an implantable medical device, in particular a stent-catheter assembly. In one embodiment, the device, as described above, can also be enclosed in a container or package. The container or package can include a sealable flexible metallic or plastic pouch that is conventionally used for storage and shipping a stent-catheter assembly. Generally, the pouch protects the assembly from exposure to air, moisture, and light.
In an embodiment, a container or package of a stent-catheter assembly includes a chipboard box and a pouch that is disposed within the box. Typically, stent-catheter assemblies are sterilized after packaging by methods such as E-beam sterilization. A packaged stent-catheter assembly is supported on a fixture during sterilization. The fixture is typically moved on a conveyer arrangement past a radiation beam from a radiation source in a manner that the radiation beam is directed onto the stent-catheter assembly. Alternatively, the radiation source can be moved with respect to the fixture.
In a cold E-beam sterilization process, the stent-catheter assembly can be cooled prior to and/or after sterilization. Additionally or alternatively, the temperature of the stent-catheter assembly can be controlled at a reduced temperature during E-beam sterilization. The stent-catheter assembly can be cooled to a reduced temperature below an ambient temperature which can refer to a temperature between about 15-30° C. In various embodiments, reduced temperature can be less than 10° C., 0° C., −15° C., −25° C., −40° C., −70° C., −100° C., −150° C., −200° C., −240° C., or less than −270° C. The stent-catheter assembly can be cooled by various methods. For example, the cooling prior to sterilization can be performed by disposing the stent-catheter assembly in a freezer for a time sufficient to cool the stent-catheter assembly to a desired temperature.
a) depicts a schematic illustration of a front view of a fixture 310 supporting two packages 320, each containing a stent-catheter assembly 305 having a stent 330 and catheter 340. Packages 320 can be, for example, a chipboard box containing the stent-catheter assembly disposed within a pouch.
In some embodiments, fixture 310 in
c) depicts a photograph of front view of fixture 310 supporting two chipboard boxes 320. Fixture 310 includes a metal plate 312 and a support arm 315 that supports boxes 320. Behind chipboard boxes 320 is a foam slab 330. Behind foam slab 330 is support arm 315 of fixture 310 that supports boxes 320. Chipboard boxes 320 are held onto support arm 315 of fixture 310 by fasteners 340. Chipboard boxes can include a stent-catheter assembly that is encased in a pouch (not shown).
In such an arrangement shown in
With reference to
Sterilization of two devices with two passes of radiation is time consuming and thus, reduces manufacturing efficiency and throughput. An exemplary fixture may allow only two devices to be sterilized at a time using two passes, one for the front and the other for the back of the devices. The devices can be cooled prior to the second irradiation step to reduce or eliminate chemical and/or mechanical degradation of the polymer of the stent caused by high radiation doses. Thus, sterilization of two devices with two passes of radiation is even more time consuming when the devices must be cooled in between passes of radiation. In some embodiments, the cooling time can be several hours, for example, 12 hours. Thus, cooling before the first pass can be 12 hours, cooling after the first pass can be 12 hours, and cooling after the second pass can be 12 hours.
Additionally, it is desired to deliver a radiation dose to a device in a predictable, narrow range. In this way, reproducibility of the dosage from device to device may be achieved. As described above, one or two devices may be irradiated during one pass of radiation. Such methods of sterilization are limited in their capacity to deliver consistent doses with a narrow range of radiation exposure from device to device.
In the embodiments described herein, multiple devices can be irradiated and sufficiently sterilized with one pass of irradiation. In such embodiments, the orientation of the devices on the fixture in relation to the beam (e.g., the orientation of the face of the package in
Thus, the embodiments provide a method and apparatus for sterilizing multiple devices at once. Multiple devices are positioned on a fixture during the single pass of radiation so that all of the devices are exposed to a radiation in such a way that the radiation dose from device to device falls within a narrow range. As a result, the methods and apparatus provide good reproducibility from device to device.
a)-(d) illustrate schematic embodiments of the present invention.
Packages 410 are staggered so that there is a non-overlapping portion 452 between adjacent packages. As a result, packages 410 are positioned so that the face of the packages is at an acute angle, θ, relative to the direction of the radiation beam 450. In one embodiment, packages 410 are positioned such that θ is between 35-45 degrees, or more narrowly 45 degrees. Fixture 420 in
As shown in
Additionally, backscattering of radiation from metallic support element or side arm 427 to packages 410 and devices contained within can increase the radiation exposure to the devices. Backscatter of radiation, such as electrons, is caused when the electrons hit a dense material (such as a metallic fixture) and are reflected back. The exposure due to backscatter can be desirable since the portions of the device closer to side arm 427 have reduced radiation exposure since radiation exposure varies with penetration depth, as described below. The backscatter of at least some radiation compensates for the reduced exposure. However, as shown in
In general, the thicker and/or denser a material is, the more it will scatter electrons, creating a “shadow” or lower dose area behind the dense material. In one embodiment, the densest part of fixture is placed towards the back to prevent it from shadowing other parts of the device. For example, as pictured in
c) depicts an overhead view of a system similar to
d) is a schematic illustration of a front view of the fixture of
Radiation shield 470 is positioned on the back end of fixture 420 to shield packages 410 from backscatter of the radiation from side arm 427. Radiation shield 470 can reduce or eliminate the difference in radiation exposure between devices near back end 475 and those behind due to backscattering of radiation. Radiation backscattered from side arm 427 can be modified prior to irradiating the devices located near back end 475 of the stack of devices on fixture 420, thereby providing greater uniformity in radiation exposure to the devices. Radiation shield 475 can also act effectively as a “dummy device.” In an embodiment, radiation shield 470 can provide shielding so that the devices near the back end receives the same or similar exposure from backscattered radiation as devices at the front end. The thickness and density of the radiation barrier can be selected to obtain a desired exposure to devices.
Thus, one or more radiation shields can increase the uniformity of the dose received over the multitude of devices positioned on fixture 420. All devices on fixture 420 can be adequately sterilized during one pass of radiation, which can increase throughput. Additionally, in a reduced temperature sterilization process, the cooling step between passes is eliminated in a one pass process, which also reduces process time.
In one embodiment, as depicted in
The dose is selected according to the devices to be sterilized. For example, a desired dose for a stent can be about 25 kGy. In one embodiment a dose of incoming radiation can be set at 35-45 kGy, or more narrowly, 40 kGy. The radiation dose received a stent can be lower than the incoming radiation due to modification of the radiation as it passes through packaging, devices, shielding, etc., as described below. Other radiation doses can be used, depending on the device to be sterilized.
The general relationship in
The curve in
Thus, radiation shields can reduce the dose of radiation that the devices are irradiated with by shifting the dose to depth curve. Since the packages are at an angle with respect to the beam, the radiation exposure varies at least as a function of “x” (
As depicted in
At various parts of the stent, radiation dose requirements may differ. However, when sterilizing multiple stent-catheter assemblies, it is preferable that the radiation dose at the stent not vary substantially from stent to stent since E-beam exposure affects properties of a material. The radiation dose received by a stent should be within a narrow range from stent to stent. At the catheter 720, a tolerance for a variation in radiation exposure is higher. The radiation exposure, for example, can be between at 20-50 kGy because the catheter is more robust than the stent for example. In contrast, the performance of a balloon, over which a stent is disposed, is much more vulnerable to degradation, thus it is desirable for its exposure to be at less than 40 kGy. Performance of stent 710 and balloon 725 are more sensitive to changes in properties, and thus, radiation exposure. Performance of catheter 720 is less sensitive to various properties, so a greater variation of radiation exposure for the catheter is more tolerable.
Dose mapping may be used to monitor the range of radiation dose received by selected portions of irradiated devices. Dose mapping refers to measuring radiation exposure at specific areas of an irradiated package and device within the package.
In one embodiment, devices are irradiated at a reduced temperature and “Targeted Dose” process. The device may be cooled prior to, during, or after sterilization. The stent can be cooled in a variety of ways, including, but not limited to, cooling the stent in a freezer, blowing a cold gas on the stent, placing the stent in proximity to a cold medium such as ice, dry ice, freezable gel, liquid nitrogen, etc.
The storage package for the implantable medical device, such as a stent, can be designed in any convenient form, shape and size that permits the effective enclosure of a stent contained therein. For example, a flexible pouch made from a polymer, glass, ceramic, metallic substance, or a combination thereof. Package can be made from metal, foam, plastic etc. For example, a material with micro-voids, such as foam, or particles, can scatter E-beam radiation which results in the more even distribution. “Foam” can refer to a polymer foam, for example, polystyrene foam such as Styrofoam from Dow Chemical Company, Midland, Mich. Thus, the package material can also be made of a material that distributes radiation more uniformly such as foam.
The package may be compact and shaped so as to minimize storage space occupied by the package. For example, without limitation, the package can be in the shape of a tube, box or a pouch. In one embodiment, the package can have a rectangular cross-section with a width between 8 in and 12 in and a length between 10 in and 13 in. Also, depending on the types of substance(s) used to construct the package, the package can be of various degrees of rigidity or flexibility.
Such packages can be stored individually or stored together with other packaged stents. For example, a pouch can be disposed in a box, such as chipboard box. The chipboard box can then be stored individually or along with a number of similar or identical packages including stents.
The package may be made of a metallic substance, the package for example can be formed of a metallic film. Suitable examples of films include, but are not limited to, gold, platinum, platinum/iridium alloy, tantalum, palladium, chromium, and aluminum. Suitable materials for the package may also include oxides of the above-mentioned metals, for example, aluminum oxide. Medical storage packages may be obtained from, for example, Oliver Devices Company of Grand Rapids, Mich.
A polymer for use in fabricating an implantable medical device, such as a stent, can be biostable, bioabsorbable, biodegradable or bioerodable. Biostable refers to polymers that are not biodegradable. The terms biodegradable, bioabsorbable, and bioerodable are used interchangeably and refer to polymers that are capable of being completely degraded and/or eroded when exposed to bodily fluids such as blood and can be gradually resorbed, absorbed and/or eliminated by the body. The processes of breaking down and absorption of the polymer can be caused by, for example, hydrolysis and metabolic processes. For stents made from a biodegradable polymer, the stent is intended to remain in the body for a duration of time until its intended function of, for example, maintaining vascular patency and/or drug delivery is accomplished.
The device may also be made of a metallic material or an alloy such as, but not limited to, a biodegradable metal.
The device may also include a drug or active agent that can include, but is not limited to, any substance capable of exerting a therapeutic, prophylactic, or diagnostic effect. The drugs for use in the implantable medical device, such as a stent or non-load bearing scaffolding structure may be of any or a combination of a therapeutic, prophylactic, or diagnostic agents. The drug can be incorporated in a polymer substrate or in a coating on the substrate that includes the drug within a polymer carrier.
While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects.
Three experiments were performed to map the dose distribution on a biodegradable stent and delivery system using a fixture as depicted in
In the first experiment, no radiation shield of foam was positioned at the front end or back end of the fixture. The delivered dose range absorbed by the stents ranged from 15.88 to 20.96 kGy, or a ratio of 1:32.
In the second experiment, a radiation shield of foam was positioned at the front end of the fixture. The results indicated a reduction in the dose spread absorbed by the stents ranged from 22.49 to 25.48 kGy, or a ratio of 1:14. It is believed that the backscatter from the aluminum fixture at the back end was contributing to scatter, and thus, the spread.
In the third experiment, a radiation shield of foam was added to both the front end and the back end of the fixture. In other words, a radiation shield was positioned on both ends of the stack of devices. On the back end of the fixture, the spread of radiation absorbed by the stents ranged from 23.89 to 26.6 kGy, or a ratio of 1:11. This experiment was repeated to confirm the results, having a ratio of 1:05. Thus, a radiation shield positioned at both ends of the stack of devices on the fixture provided the narrowest spread of radiation dose among the devices positioned on the fixture.
Number | Name | Date | Kind |
---|---|---|---|
RE23195 | Brasch | Feb 1950 | E |
3687135 | Stroganov et al. | Aug 1972 | A |
3839743 | Schwarcz | Oct 1974 | A |
3900632 | Robinson | Aug 1975 | A |
4104410 | Malecki | Aug 1978 | A |
4110497 | Hoel | Aug 1978 | A |
4321711 | Mano | Mar 1982 | A |
4346028 | Griffith | Aug 1982 | A |
4596574 | Urist | Jun 1986 | A |
4599085 | Riess et al. | Jul 1986 | A |
4612009 | Drobnik et al. | Sep 1986 | A |
4633873 | Dumican et al. | Jan 1987 | A |
4656083 | Hoffman et al. | Apr 1987 | A |
4718907 | Karwoski et al. | Jan 1988 | A |
4722335 | Vilasi | Feb 1988 | A |
4723549 | Wholey et al. | Feb 1988 | A |
4732152 | Wallstén et al. | Mar 1988 | A |
4733665 | Palmaz | Mar 1988 | A |
4739762 | Palmaz | Apr 1988 | A |
4740207 | Kreamer | Apr 1988 | A |
4743252 | Martin, Jr. et al. | May 1988 | A |
4768507 | Fischell et al. | Sep 1988 | A |
4776337 | Palmaz | Oct 1988 | A |
4800882 | Gianturco | Jan 1989 | A |
4816339 | Tu et al. | Mar 1989 | A |
4818559 | Hama et al. | Apr 1989 | A |
4850999 | Planck | Jul 1989 | A |
4877030 | Beck et al. | Oct 1989 | A |
4878906 | Lindemann et al. | Nov 1989 | A |
4879135 | Greco et al. | Nov 1989 | A |
4886062 | Wiktor | Dec 1989 | A |
4902289 | Yannas | Feb 1990 | A |
4977901 | Ofstead | Dec 1990 | A |
4994298 | Yasuda | Feb 1991 | A |
5019090 | Pinchuk | May 1991 | A |
5028597 | Kodama et al. | Jul 1991 | A |
5059211 | Stack et al. | Oct 1991 | A |
5062829 | Pryor et al. | Nov 1991 | A |
5084065 | Weldon et al. | Jan 1992 | A |
5085629 | Goldberg et al. | Feb 1992 | A |
5100429 | Sinofsky et al. | Mar 1992 | A |
5104410 | Chowdhary | Apr 1992 | A |
5108417 | Sawyer | Apr 1992 | A |
5108755 | Daniels et al. | Apr 1992 | A |
5112457 | Marchant | May 1992 | A |
5123917 | Lee | Jun 1992 | A |
5156623 | Hakamatsuka et al. | Oct 1992 | A |
5163951 | Pinchuk et al. | Nov 1992 | A |
5163952 | Froix | Nov 1992 | A |
5163958 | Pinchuk | Nov 1992 | A |
5167614 | Tessmann et al. | Dec 1992 | A |
5192311 | King et al. | Mar 1993 | A |
5197977 | Hoffman, Jr. et al. | Mar 1993 | A |
5234456 | Silvestrini | Aug 1993 | A |
5234457 | Andersen | Aug 1993 | A |
5236447 | Kubo et al. | Aug 1993 | A |
5279594 | Jackson | Jan 1994 | A |
5282860 | Matsuno et al. | Feb 1994 | A |
5289831 | Bosley | Mar 1994 | A |
5290271 | Jernberg | Mar 1994 | A |
5306286 | Stack et al. | Apr 1994 | A |
5306294 | Winston et al. | Apr 1994 | A |
5328471 | Slepian | Jul 1994 | A |
5330500 | Song | Jul 1994 | A |
5342348 | Kaplan | Aug 1994 | A |
5342395 | Jarrett et al. | Aug 1994 | A |
5342621 | Eury et al. | Aug 1994 | A |
5356433 | Rowland et al. | Oct 1994 | A |
5383925 | Schmitt | Jan 1995 | A |
5385580 | Schmitt | Jan 1995 | A |
5389106 | Tower | Feb 1995 | A |
5399666 | Ford | Mar 1995 | A |
5423885 | Williams | Jun 1995 | A |
5441515 | Khosravi et al. | Aug 1995 | A |
5443458 | Eury et al. | Aug 1995 | A |
5443500 | Sigwart | Aug 1995 | A |
5455040 | Marchant | Oct 1995 | A |
5464650 | Berg et al. | Nov 1995 | A |
5502158 | Sinclair et al. | Mar 1996 | A |
5514379 | Weissleder et al. | May 1996 | A |
5527337 | Stack et al. | Jun 1996 | A |
5545408 | Trigg et al. | Aug 1996 | A |
5554120 | Chen et al. | Sep 1996 | A |
5556413 | Lam | Sep 1996 | A |
5578046 | Liu et al. | Nov 1996 | A |
5578073 | Haimovich et al. | Nov 1996 | A |
5591199 | Porter et al. | Jan 1997 | A |
5591607 | Gryaznov et al. | Jan 1997 | A |
5593403 | Buscemi | Jan 1997 | A |
5593434 | Williams | Jan 1997 | A |
5599301 | Jacobs et al. | Feb 1997 | A |
5599922 | Gryaznov et al. | Feb 1997 | A |
5605696 | Eury et al. | Feb 1997 | A |
5607442 | Fischell et al. | Mar 1997 | A |
5607467 | Froix | Mar 1997 | A |
5618299 | Khosravi et al. | Apr 1997 | A |
5629077 | Turnlund et al. | May 1997 | A |
5631135 | Gryaznov et al. | May 1997 | A |
5632771 | Boatman et al. | May 1997 | A |
5632840 | Campbell | May 1997 | A |
5637113 | Tartaglia et al. | Jun 1997 | A |
5649977 | Campbell | Jul 1997 | A |
5667767 | Greff et al. | Sep 1997 | A |
5667796 | Otten | Sep 1997 | A |
5670558 | Onishi et al. | Sep 1997 | A |
5693085 | Buirge et al. | Dec 1997 | A |
5700286 | Tartaglia et al. | Dec 1997 | A |
5707385 | Williams | Jan 1998 | A |
5711763 | Nonami et al. | Jan 1998 | A |
5716981 | Hunter et al. | Feb 1998 | A |
5725549 | Lam | Mar 1998 | A |
5726297 | Gryaznov et al. | Mar 1998 | A |
5728751 | Patnaik | Mar 1998 | A |
5733326 | Tomonto et al. | Mar 1998 | A |
5733330 | Cox | Mar 1998 | A |
5733564 | Lehtinen | Mar 1998 | A |
5733925 | Kunz et al. | Mar 1998 | A |
5741881 | Patnaik | Apr 1998 | A |
5756457 | Wang et al. | May 1998 | A |
5756476 | Epstein et al. | May 1998 | A |
5765682 | Bley et al. | Jun 1998 | A |
5766204 | Porter et al. | Jun 1998 | A |
5766239 | Cox | Jun 1998 | A |
5766710 | Turnlund et al. | Jun 1998 | A |
5769883 | Buscemi et al. | Jun 1998 | A |
5780807 | Saunders | Jul 1998 | A |
5800516 | Fine et al. | Sep 1998 | A |
5811447 | Kunz et al. | Sep 1998 | A |
5824049 | Ragheb et al. | Oct 1998 | A |
5830178 | Jones et al. | Nov 1998 | A |
5830461 | Billiar et al. | Nov 1998 | A |
5830879 | Isner | Nov 1998 | A |
5833651 | Donovan et al. | Nov 1998 | A |
5834582 | Sinclair et al. | Nov 1998 | A |
5836962 | Gianotti | Nov 1998 | A |
5837313 | Ding et al. | Nov 1998 | A |
5837835 | Gryaznov et al. | Nov 1998 | A |
5840083 | Braach-Maksvytis | Nov 1998 | A |
5851508 | Greff et al. | Dec 1998 | A |
5853408 | Muni | Dec 1998 | A |
5854207 | Lee et al. | Dec 1998 | A |
5855612 | Ohthuki et al. | Jan 1999 | A |
5855618 | Patnaik et al. | Jan 1999 | A |
5858746 | Hubbell et al. | Jan 1999 | A |
5865814 | Tuch | Feb 1999 | A |
5868781 | Killion | Feb 1999 | A |
5873904 | Ragheb et al. | Feb 1999 | A |
5874101 | Zhong et al. | Feb 1999 | A |
5874109 | Ducheyne et al. | Feb 1999 | A |
5874165 | Drumheller | Feb 1999 | A |
5876743 | Ibsen et al. | Mar 1999 | A |
5877263 | Patnaik et al. | Mar 1999 | A |
5879713 | Roth et al. | Mar 1999 | A |
5888533 | Dunn | Mar 1999 | A |
5891192 | Murayama et al. | Apr 1999 | A |
5897955 | Drumheller | Apr 1999 | A |
5906759 | Richter | May 1999 | A |
5914182 | Drumheller | Jun 1999 | A |
5916870 | Lee et al. | Jun 1999 | A |
5922005 | Richter et al. | Jul 1999 | A |
5942209 | Leavitt et al. | Aug 1999 | A |
5948428 | Lee et al. | Sep 1999 | A |
5954744 | Phan et al. | Sep 1999 | A |
5957975 | Lafont et al. | Sep 1999 | A |
5965720 | Gryaznov et al. | Oct 1999 | A |
5971954 | Conway et al. | Oct 1999 | A |
5976182 | Cox | Nov 1999 | A |
5980564 | Stinson | Nov 1999 | A |
5980928 | Terry | Nov 1999 | A |
5980972 | Ding | Nov 1999 | A |
5981568 | Kunz et al. | Nov 1999 | A |
5986169 | Gjunter | Nov 1999 | A |
5997468 | Wolff et al. | Dec 1999 | A |
6010445 | Armini et al. | Jan 2000 | A |
6015541 | Greff et al. | Jan 2000 | A |
6042875 | Ding et al. | Mar 2000 | A |
6048964 | Lee et al. | Apr 2000 | A |
6051648 | Rhee et al. | Apr 2000 | A |
6056993 | Leidner et al. | May 2000 | A |
6060451 | DiMaio et al. | May 2000 | A |
6066156 | Yan | May 2000 | A |
6071266 | Kelley | Jun 2000 | A |
6074659 | Kunz et al. | Jun 2000 | A |
6080177 | Igaki et al. | Jun 2000 | A |
6080488 | Hostettler et al. | Jun 2000 | A |
6083258 | Yadav | Jul 2000 | A |
6093463 | Thakrar | Jul 2000 | A |
6096070 | Ragheb et al. | Aug 2000 | A |
6096525 | Patnaik | Aug 2000 | A |
6099562 | Ding et al. | Aug 2000 | A |
6103230 | Billiar et al. | Aug 2000 | A |
6107416 | Patnaik et al. | Aug 2000 | A |
6110188 | Narciso, Jr. | Aug 2000 | A |
6113629 | Ken | Sep 2000 | A |
6117979 | Hendriks et al. | Sep 2000 | A |
6120536 | Ding et al. | Sep 2000 | A |
6120904 | Hostettler et al. | Sep 2000 | A |
6121027 | Clapper et al. | Sep 2000 | A |
6125523 | Brown et al. | Oct 2000 | A |
6127173 | Eckstein et al. | Oct 2000 | A |
6129761 | Hubbell | Oct 2000 | A |
6129928 | Sarangapani et al. | Oct 2000 | A |
6150630 | Perry et al. | Nov 2000 | A |
6153252 | Hossainy et al. | Nov 2000 | A |
4776337 | Palmaz | Dec 2000 | A |
6159951 | Karpeisky et al. | Dec 2000 | A |
6160084 | Langer et al. | Dec 2000 | A |
6165212 | Dereume et al. | Dec 2000 | A |
6166130 | Rhee et al. | Dec 2000 | A |
6169170 | Gryaznov et al. | Jan 2001 | B1 |
6171609 | Kunz | Jan 2001 | B1 |
6174330 | Stinson | Jan 2001 | B1 |
6177523 | Reich et al. | Jan 2001 | B1 |
6183505 | Mohn, Jr. et al. | Feb 2001 | B1 |
6187045 | Fehring et al. | Feb 2001 | B1 |
6210715 | Starling et al. | Apr 2001 | B1 |
6224626 | Steinke | May 2001 | B1 |
6228845 | Donovan et al. | May 2001 | B1 |
6240616 | Yan | Jun 2001 | B1 |
6245076 | Yan | Jun 2001 | B1 |
6245103 | Stinson | Jun 2001 | B1 |
6248344 | Ylanen et al. | Jun 2001 | B1 |
6251135 | Stinson et al. | Jun 2001 | B1 |
6251142 | Bernacca et al. | Jun 2001 | B1 |
6273913 | Wright et al. | Aug 2001 | B1 |
6281262 | Shikinami | Aug 2001 | B1 |
6284333 | Wang et al. | Sep 2001 | B1 |
6287332 | Bolz et al. | Sep 2001 | B1 |
6290721 | Heath | Sep 2001 | B1 |
6293966 | Frantzen | Sep 2001 | B1 |
6303901 | Perry et al. | Oct 2001 | B1 |
6312459 | Huang et al. | Nov 2001 | B1 |
6327772 | Zadno-Azizi et al. | Dec 2001 | B1 |
4733665 | Palmaz | Jan 2002 | C2 |
6375826 | Wang et al. | Apr 2002 | B1 |
6379381 | Hossainy et al. | Apr 2002 | B1 |
6387121 | Alt | May 2002 | B1 |
6388043 | Langer et al. | May 2002 | B1 |
6395326 | Castro et al. | May 2002 | B1 |
6409761 | Jang | Jun 2002 | B1 |
6423092 | Datta et al. | Jul 2002 | B2 |
6461632 | Gogolewski | Oct 2002 | B1 |
6464720 | Boatman et al. | Oct 2002 | B2 |
6479565 | Stanley | Nov 2002 | B1 |
6485512 | Cheng | Nov 2002 | B1 |
6492615 | Flanagan | Dec 2002 | B1 |
6494908 | Huxel et al. | Dec 2002 | B1 |
6495156 | Wenz et al. | Dec 2002 | B2 |
6511748 | Barrows | Jan 2003 | B1 |
6517888 | Weber | Feb 2003 | B1 |
6527801 | Dutta | Mar 2003 | B1 |
6537589 | Chae et al. | Mar 2003 | B1 |
6539607 | Fehring et al. | Apr 2003 | B1 |
6540777 | Stenzel | Apr 2003 | B2 |
6554854 | Flanagan | Apr 2003 | B1 |
6565599 | Hong et al. | May 2003 | B1 |
6569191 | Hogan | May 2003 | B1 |
6569193 | Cox et al. | May 2003 | B1 |
6572672 | Yadav et al. | Jun 2003 | B2 |
6574851 | Mirizzi | Jun 2003 | B1 |
6585755 | Jackson et al. | Jul 2003 | B2 |
6592614 | Lenker et al. | Jul 2003 | B2 |
6592617 | Thompson | Jul 2003 | B2 |
6613072 | Lau et al. | Sep 2003 | B2 |
6626939 | Burnside et al. | Sep 2003 | B1 |
6635269 | Jennissen | Oct 2003 | B1 |
6645243 | Vallana et al. | Nov 2003 | B2 |
6656162 | Santini, Jr. et al. | Dec 2003 | B2 |
6664335 | Krishnan | Dec 2003 | B2 |
6666214 | Canham | Dec 2003 | B2 |
6667049 | Janas et al. | Dec 2003 | B2 |
6669723 | Killion et al. | Dec 2003 | B2 |
6676697 | Richter | Jan 2004 | B1 |
6679980 | Andreacchi | Jan 2004 | B1 |
6689375 | Wahlig et al. | Feb 2004 | B1 |
6695920 | Pacetti et al. | Feb 2004 | B1 |
6706273 | Roessler | Mar 2004 | B1 |
6709379 | Brandau et al. | Mar 2004 | B1 |
6719934 | Stinson | Apr 2004 | B2 |
6719989 | Matsushima et al. | Apr 2004 | B1 |
6720402 | Langer et al. | Apr 2004 | B2 |
6746773 | Llanos et al. | Jun 2004 | B2 |
6752826 | Holloway et al. | Jun 2004 | B2 |
6753007 | Haggard et al. | Jun 2004 | B2 |
6764505 | Hossainy et al. | Jul 2004 | B1 |
6806476 | Rose et al. | Oct 2004 | B2 |
6818063 | Kerrigan | Nov 2004 | B1 |
6846323 | Yip et al. | Jan 2005 | B2 |
7166099 | Devens, Jr. | Jan 2007 | B2 |
20010044652 | Moore | Nov 2001 | A1 |
20020002399 | Huxel et al. | Jan 2002 | A1 |
20020004060 | Heublein et al. | Jan 2002 | A1 |
20020004101 | Ding et al. | Jan 2002 | A1 |
20020062148 | Hart | May 2002 | A1 |
20020065553 | Weber | May 2002 | A1 |
20020111590 | Davila et al. | Aug 2002 | A1 |
20020116050 | Kocur | Aug 2002 | A1 |
20020138133 | Lenz et al. | Sep 2002 | A1 |
20020161114 | Gunatillake et al. | Oct 2002 | A1 |
20030033001 | Igaki | Feb 2003 | A1 |
20030065355 | Weber | Apr 2003 | A1 |
20030093107 | Parsonage et al. | May 2003 | A1 |
20030100865 | Santini, Jr. et al. | May 2003 | A1 |
20030105518 | Dutta | Jun 2003 | A1 |
20030105530 | Pirhonen et al. | Jun 2003 | A1 |
20030171053 | Sanders | Sep 2003 | A1 |
20030187495 | Cully et al. | Oct 2003 | A1 |
20030208259 | Penhasi | Nov 2003 | A1 |
20030209835 | Chun et al. | Nov 2003 | A1 |
20030215354 | Clark et al. | Nov 2003 | A1 |
20030226833 | Shapovalov et al. | Dec 2003 | A1 |
20030236563 | Fifer | Dec 2003 | A1 |
20040093077 | White et al. | May 2004 | A1 |
20040098095 | Burnside et al. | May 2004 | A1 |
20040111149 | Stinson | Jun 2004 | A1 |
20040127970 | Saunders et al. | Jul 2004 | A1 |
20040143317 | Stinson et al. | Jul 2004 | A1 |
20040167610 | Fleming, III | Aug 2004 | A1 |
20050013729 | Brown-Skrobot et al. | Jan 2005 | A1 |
20050233062 | Hossainy et al. | Oct 2005 | A1 |
20060067974 | Labrecque et al. | Mar 2006 | A1 |
20070065334 | Shalaby | Mar 2007 | A1 |
Number | Date | Country |
---|---|---|
44 07 079 | Sep 1994 | DE |
197 31 021 | Jan 1999 | DE |
198 56 983 | Dec 1999 | DE |
0 108 171 | May 1984 | EP |
0 144 534 | Jun 1985 | EP |
0 218 003 | Apr 1987 | EP |
0 364 787 | Apr 1990 | EP |
0 397 500 | Nov 1990 | EP |
0 464 755 | Jan 1992 | EP |
0 493 788 | Jul 1992 | EP |
0 554 082 | Aug 1993 | EP |
0 578 998 | Jan 1994 | EP |
0 604 022 | Jun 1994 | EP |
0 621 017 | Oct 1994 | EP |
0 623 354 | Nov 1994 | EP |
0 665 023 | Aug 1995 | EP |
0 709 068 | May 1996 | EP |
0 970 711 | Jan 2000 | EP |
2 247 696 | Mar 1992 | GB |
11 133196 | May 1999 | JP |
2000 334028 | Dec 2000 | JP |
WO 8903232 | Apr 1989 | WO |
WO 9001969 | Mar 1990 | WO |
WO 9004982 | May 1990 | WO |
WO 9006094 | Jun 1990 | WO |
WO 9117744 | Nov 1991 | WO |
WO 9117789 | Nov 1991 | WO |
WO 9210218 | Jun 1992 | WO |
WO 9306792 | Apr 1993 | WO |
WO 9421196 | Sep 1994 | WO |
WO 9529647 | Nov 1995 | WO |
WO 9804415 | Feb 1998 | WO |
WO 9903515 | Jan 1999 | WO |
WO 9916386 | Apr 1999 | WO |
WO 9942147 | Aug 1999 | WO |
WO 0012147 | Mar 2000 | WO |
WO 0064506 | Nov 2000 | WO |
WO 0101890 | Jan 2001 | WO |
WO 03037390 | May 2003 | WO |
WO 2004023985 | Mar 2004 | WO |
WO 2006034157 | Mar 2006 | WO |
Number | Date | Country | |
---|---|---|---|
20080299002 A1 | Dec 2008 | US |